Brief: BiondVax - Last Of 12,400 Participants Completes Final Visit In Biondvax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

Scinai Immunotherapeutics

01/07/2020 11:25

July 1 (Reuters) - BiondVax Pharmaceuticals Ltd  2F5.F :
    * LAST OF 12,400 PARTICIPANTS COMPLETES FINAL VISIT IN
BIONDVAX'S
M-001 UNIVERSAL FLU VACCINE PIVOTAL PHASE 3 CLINICAL TRIAL
    * BIONDVAX PHARMACEUTICALS - EQUIPMENT INSTALLATION,
MANUFACTURING
PROCESS SCALE-UP IN BIONDVAX'S PILOT FACILITY IN JERUSALEM ARE
IN PROGRESS

Source text for Eikon:  ID:nPnZjqdga 
Further company coverage:  2F5.F 

 ((Briefs@thomsonreuters.com;))